Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03661606
Other study ID # PIEC/2018/013
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 30, 2018
Est. completion date October 4, 2018

Study information

Verified date October 2018
Source Biofourmis Singapore Pte Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Unexpected adverse health events resulting in a hospital admission can be potentially avoided by leveraging novel physiological sensors combined with advanced computational techniques to predict changes in physiology prior to the onset of symptoms. In other words, significant improvement in the prevention of avoidable hospitalization can be achieved via early detection and actionable insights of clinical deterioration at the individual patient level as they go about their normal day to day activities. Physiological changes can be a warning sign that a person's health is deteriorating and as such is an important component of an early detection tool.

The Biovitals Analytics Engine (BA Engine) is intended to be used with data from already validated sensors measuring physiological parameters, including heart rate (HR), respiratory rate (RR) and activity in ambulatory patients being monitored in a healthcare facility or at home. The device provides a continuous output- Biovitals™ Index (BI) which indicates whether the relationships among the patients monitored vital signs change from those measured at baseline (derived from measurements previously obtained during daily routine activities). The BI is based on an integrated computation evaluating changes in the parameters and their relationship to each other.

As part of the clinical validation of the BA Engine, it is important to first undertake an analytical validation to demonstrate that the BA correctly processes the physiological data for which it is designed, and generates an accurate detection of physiological change. In order to generate a measurable physiological change, subjects will move from sea level to an altitude environment which is known to cause increases in HR and RR.


Description:

Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.

Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with an altitude change of 3000 meters. At the chamber site, the subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow-up phone call to check on subjects will then be done on day 5 before closing the study.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date October 4, 2018
Est. primary completion date September 30, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- 50 Male or female, voluntary adults aged between = 18 to = 65 years

- Ability to read and understand basic English Language

- Women who are of childbearing potential, must if sexually active, agree to use appropriate contraceptive measures for the duration of the study

- Able to perform all activities in the study procedure

Exclusion Criteria:

- High altitude residents (>500m)

- Anemic

- Athlete

- Lung, airways and/or sinus pathology

- Previous myocardial infarction or coronary revascularization (PCI or CABG)

- Any prior history of heart failure

- Any prior history of moderate or severe valvular heart disease

- Any history of pulmonary disease (asthma, emphysema/ COPD, pulmonary hypertension)

- Any other medical condition or functional problems (e.g. previous intolerance or current contraindication to altitude, unable to exercise, skin problems, schizophrenia and bipolar disorder) that in the judgment of the investigator will impair the subjects ability to complete the processes needed in the clinical study

- Unable or unwillingness to sign the informed consent

- Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Simulated Altitude Chamber
Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days. Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with altitude change of 3000 meters. At the chamber site, subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow up phone call to check on subjects will then be done on day 5 before closing the study.

Locations

Country Name City State
Singapore Singapore Aeromedical Centre Singapore

Sponsors (1)

Lead Sponsor Collaborator
Biofourmis Singapore Pte Ltd.

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Analytical validation testing of the BA Engine's output This study aims to demonstrate that the BA Engine correctly processes monitored physiological data to generate accurate, reliable and precise detection of changes in an individual's physiology at high altitude (3000m) when compared to their baseline physiology at sea-level, as per its design specifications and to meet its intended use. Changes in subjects physiology at an altitude of 3000m compared to baseline physiology
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1